targetId
stringlengths 15
15
| diseaseId
stringlengths 9
15
| nctid
stringlengths 11
11
⌀ | clinicalStatus
stringclasses 9
values | clinicalPhase
int64 0
4
| studyStartDate
stringdate 1965-04-01 00:00:00
2050-12-01 00:00:00
⌀ | stopStatus
stringclasses 3
values | isStopped
stringclasses 1
value | phase4
stringclasses 1
value | phase3
stringclasses 1
value | phase2
stringclasses 1
value | id
int64 0
1,709B
| why_stopped
stringlengths 2
254
⌀ | phase
stringclasses 7
values | start_date
stringlengths 10
10
⌀ | status
stringclasses 3
values | last_update_posted_date
stringlengths 10
10
⌀ | completion_date
stringlengths 10
10
⌀ | prediction
stringclasses 15
values | metaprediction
stringclasses 6
values | max_l2g
float64 0.05
0.9
⌀ | l2g_075
stringclasses 1
value | l2g_05
stringclasses 1
value | l2g_025
stringclasses 1
value | l2g_01
stringclasses 1
value | l2g_005
stringclasses 1
value | taId
stringclasses 23
values | taLabel
stringclasses 24
values | taLabelSimple
stringclasses 2
values | gc
float64 0
5
⌀ | lof_tolerance
stringclasses 2
values | rnaDistribution
stringclasses 5
values | rnaSpecificity
stringclasses 5
values | partnersBin
stringclasses 4
values | datasourceId
stringclasses 22
values | datatypeId
stringclasses 7
values | total
int64 413k
413k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ENSG00000258947
|
MONDO_0001187
|
NCT00055601
|
Completed
| 2
|
2002-12-01
| null | null | null | null |
Phase II+
| 1,546,188,226,810
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
slapenrich
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00055601
|
Completed
| 2
|
2002-12-01
| null | null | null | null |
Phase II+
| 1,546,188,226,810
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
cancer_biomarkers
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00055601
|
Completed
| 2
|
2002-12-01
| null | null | null | null |
Phase II+
| 1,546,188,226,810
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00055601
|
Completed
| 2
|
2002-12-01
| null | null | null | null |
Phase II+
| 1,546,188,226,810
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00055601
|
Completed
| 2
|
2002-12-01
| null | null | null | null |
Phase II+
| 1,546,188,226,810
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
slapenrich
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00506155
|
Completed
| 2
|
2007-06-01
| null | null | null | null |
Phase II+
| 1,571,958,031,733
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 0
|
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
cancer_biomarkers
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00506155
|
Completed
| 2
|
2007-06-01
| null | null | null | null |
Phase II+
| 1,571,958,031,733
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 0
|
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00506155
|
Completed
| 2
|
2007-06-01
| null | null | null | null |
Phase II+
| 1,571,958,031,733
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 0
|
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00506155
|
Completed
| 2
|
2007-06-01
| null | null | null | null |
Phase II+
| 1,571,958,031,733
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 0
|
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
slapenrich
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00506155
|
Completed
| 2
|
2007-06-01
| null | null | null | null |
Phase II+
| 1,571,958,031,733
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
cancer_biomarkers
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00506155
|
Completed
| 2
|
2007-06-01
| null | null | null | null |
Phase II+
| 1,571,958,031,733
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00506155
|
Completed
| 2
|
2007-06-01
| null | null | null | null |
Phase II+
| 1,571,958,031,733
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00506155
|
Completed
| 2
|
2007-06-01
| null | null | null | null |
Phase II+
| 1,571,958,031,733
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
slapenrich
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00506155
|
Completed
| 2
|
2007-06-01
| null | null | null | null |
Phase II+
| 1,571,958,031,733
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
cancer_biomarkers
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00506155
|
Completed
| 2
|
2007-06-01
| null | null | null | null |
Phase II+
| 1,571,958,031,733
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00506155
|
Completed
| 2
|
2007-06-01
| null | null | null | null |
Phase II+
| 1,571,958,031,733
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00506155
|
Completed
| 2
|
2007-06-01
| null | null | null | null |
Phase II+
| 1,571,958,031,733
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
slapenrich
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00028756
|
Completed
| 3
|
2001-10-01
| null | null | null |
Phase III+
|
Phase II+
| 1,640,677,508,265
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 0
|
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
cancer_biomarkers
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00028756
|
Completed
| 3
|
2001-10-01
| null | null | null |
Phase III+
|
Phase II+
| 1,640,677,508,265
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 0
|
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00028756
|
Completed
| 3
|
2001-10-01
| null | null | null |
Phase III+
|
Phase II+
| 1,640,677,508,265
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 0
|
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00028756
|
Completed
| 3
|
2001-10-01
| null | null | null |
Phase III+
|
Phase II+
| 1,640,677,508,265
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 0
|
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
slapenrich
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00028756
|
Completed
| 3
|
2001-10-01
| null | null | null |
Phase III+
|
Phase II+
| 1,640,677,508,265
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
cancer_biomarkers
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00028756
|
Completed
| 3
|
2001-10-01
| null | null | null |
Phase III+
|
Phase II+
| 1,640,677,508,265
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00028756
|
Completed
| 3
|
2001-10-01
| null | null | null |
Phase III+
|
Phase II+
| 1,640,677,508,265
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00028756
|
Completed
| 3
|
2001-10-01
| null | null | null |
Phase III+
|
Phase II+
| 1,640,677,508,265
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
slapenrich
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00028756
|
Completed
| 3
|
2001-10-01
| null | null | null |
Phase III+
|
Phase II+
| 1,640,677,508,265
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
cancer_biomarkers
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00028756
|
Completed
| 3
|
2001-10-01
| null | null | null |
Phase III+
|
Phase II+
| 1,640,677,508,265
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00028756
|
Completed
| 3
|
2001-10-01
| null | null | null |
Phase III+
|
Phase II+
| 1,640,677,508,265
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00028756
|
Completed
| 3
|
2001-10-01
| null | null | null |
Phase III+
|
Phase II+
| 1,640,677,508,265
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
slapenrich
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00003376
|
Completed
| 3
|
1998-09-01
| null | null | null |
Phase III+
|
Phase II+
| 1,640,677,508,694
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 0
|
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
cancer_biomarkers
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00003376
|
Completed
| 3
|
1998-09-01
| null | null | null |
Phase III+
|
Phase II+
| 1,640,677,508,694
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 0
|
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00003376
|
Completed
| 3
|
1998-09-01
| null | null | null |
Phase III+
|
Phase II+
| 1,640,677,508,694
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 0
|
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00003376
|
Completed
| 3
|
1998-09-01
| null | null | null |
Phase III+
|
Phase II+
| 1,640,677,508,694
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 0
|
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
slapenrich
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00003376
|
Completed
| 3
|
1998-09-01
| null | null | null |
Phase III+
|
Phase II+
| 1,640,677,508,694
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
cancer_biomarkers
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00003376
|
Completed
| 3
|
1998-09-01
| null | null | null |
Phase III+
|
Phase II+
| 1,640,677,508,694
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00003376
|
Completed
| 3
|
1998-09-01
| null | null | null |
Phase III+
|
Phase II+
| 1,640,677,508,694
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00003376
|
Completed
| 3
|
1998-09-01
| null | null | null |
Phase III+
|
Phase II+
| 1,640,677,508,694
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
slapenrich
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00003376
|
Completed
| 3
|
1998-09-01
| null | null | null |
Phase III+
|
Phase II+
| 1,640,677,508,694
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
cancer_biomarkers
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00003376
|
Completed
| 3
|
1998-09-01
| null | null | null |
Phase III+
|
Phase II+
| 1,640,677,508,694
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00003376
|
Completed
| 3
|
1998-09-01
| null | null | null |
Phase III+
|
Phase II+
| 1,640,677,508,694
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00003376
|
Completed
| 3
|
1998-09-01
| null | null | null |
Phase III+
|
Phase II+
| 1,640,677,508,694
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
slapenrich
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00003103
|
Completed
| 1
|
1997-08-01
| null | null | null | null | null | 1,666,447,311,151
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 0
|
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
cancer_biomarkers
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00003103
|
Completed
| 1
|
1997-08-01
| null | null | null | null | null | 1,666,447,311,151
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 0
|
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00003103
|
Completed
| 1
|
1997-08-01
| null | null | null | null | null | 1,666,447,311,151
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 0
|
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00003103
|
Completed
| 1
|
1997-08-01
| null | null | null | null | null | 1,666,447,311,151
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 0
|
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
slapenrich
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00003103
|
Completed
| 1
|
1997-08-01
| null | null | null | null | null | 1,666,447,311,151
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
cancer_biomarkers
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00003103
|
Completed
| 1
|
1997-08-01
| null | null | null | null | null | 1,666,447,311,151
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00003103
|
Completed
| 1
|
1997-08-01
| null | null | null | null | null | 1,666,447,311,151
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00003103
|
Completed
| 1
|
1997-08-01
| null | null | null | null | null | 1,666,447,311,151
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
slapenrich
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00003103
|
Completed
| 1
|
1997-08-01
| null | null | null | null | null | 1,666,447,311,151
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
cancer_biomarkers
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00003103
|
Completed
| 1
|
1997-08-01
| null | null | null | null | null | 1,666,447,311,151
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00003103
|
Completed
| 1
|
1997-08-01
| null | null | null | null | null | 1,666,447,311,151
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00003103
|
Completed
| 1
|
1997-08-01
| null | null | null | null | null | 1,666,447,311,151
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
slapenrich
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00022633
|
Terminated
| 2
|
2001-07-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 1,675,037,246,695
|
Permanently Closed Due to Poor Accrual
|
Phase 2
|
31/07/2001
|
Terminated
|
11/08/2016
|
31/07/2011
|
Insufficient_Enrollment
|
Neutral
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 0
|
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
cancer_biomarkers
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00022633
|
Terminated
| 2
|
2001-07-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 1,675,037,246,695
|
Permanently Closed Due to Poor Accrual
|
Phase 2
|
31/07/2001
|
Terminated
|
11/08/2016
|
31/07/2011
|
Insufficient_Enrollment
|
Neutral
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 0
|
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00022633
|
Terminated
| 2
|
2001-07-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 1,675,037,246,695
|
Permanently Closed Due to Poor Accrual
|
Phase 2
|
31/07/2001
|
Terminated
|
11/08/2016
|
31/07/2011
|
Insufficient_Enrollment
|
Neutral
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 0
|
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00022633
|
Terminated
| 2
|
2001-07-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 1,675,037,246,695
|
Permanently Closed Due to Poor Accrual
|
Phase 2
|
31/07/2001
|
Terminated
|
11/08/2016
|
31/07/2011
|
Insufficient_Enrollment
|
Neutral
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 0
|
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
slapenrich
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00022633
|
Terminated
| 2
|
2001-07-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 1,675,037,246,695
|
Permanently Closed Due to Poor Accrual
|
Phase 2
|
31/07/2001
|
Terminated
|
11/08/2016
|
31/07/2011
|
Insufficient_Enrollment
|
Neutral
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
cancer_biomarkers
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00022633
|
Terminated
| 2
|
2001-07-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 1,675,037,246,695
|
Permanently Closed Due to Poor Accrual
|
Phase 2
|
31/07/2001
|
Terminated
|
11/08/2016
|
31/07/2011
|
Insufficient_Enrollment
|
Neutral
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00022633
|
Terminated
| 2
|
2001-07-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 1,675,037,246,695
|
Permanently Closed Due to Poor Accrual
|
Phase 2
|
31/07/2001
|
Terminated
|
11/08/2016
|
31/07/2011
|
Insufficient_Enrollment
|
Neutral
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00022633
|
Terminated
| 2
|
2001-07-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 1,675,037,246,695
|
Permanently Closed Due to Poor Accrual
|
Phase 2
|
31/07/2001
|
Terminated
|
11/08/2016
|
31/07/2011
|
Insufficient_Enrollment
|
Neutral
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
slapenrich
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00022633
|
Terminated
| 2
|
2001-07-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 1,675,037,246,695
|
Permanently Closed Due to Poor Accrual
|
Phase 2
|
31/07/2001
|
Terminated
|
11/08/2016
|
31/07/2011
|
Insufficient_Enrollment
|
Neutral
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
cancer_biomarkers
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00022633
|
Terminated
| 2
|
2001-07-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 1,675,037,246,695
|
Permanently Closed Due to Poor Accrual
|
Phase 2
|
31/07/2001
|
Terminated
|
11/08/2016
|
31/07/2011
|
Insufficient_Enrollment
|
Neutral
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00022633
|
Terminated
| 2
|
2001-07-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 1,675,037,246,695
|
Permanently Closed Due to Poor Accrual
|
Phase 2
|
31/07/2001
|
Terminated
|
11/08/2016
|
31/07/2011
|
Insufficient_Enrollment
|
Neutral
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00022633
|
Terminated
| 2
|
2001-07-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 1,675,037,246,695
|
Permanently Closed Due to Poor Accrual
|
Phase 2
|
31/07/2001
|
Terminated
|
11/08/2016
|
31/07/2011
|
Insufficient_Enrollment
|
Neutral
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
slapenrich
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00004223
|
Completed
| 2
|
1999-12-01
| null | null | null | null |
Phase II+
| 1,683,627,181,300
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 0
|
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
cancer_biomarkers
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00004223
|
Completed
| 2
|
1999-12-01
| null | null | null | null |
Phase II+
| 1,683,627,181,300
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 0
|
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00004223
|
Completed
| 2
|
1999-12-01
| null | null | null | null |
Phase II+
| 1,683,627,181,300
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 0
|
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00004223
|
Completed
| 2
|
1999-12-01
| null | null | null | null |
Phase II+
| 1,683,627,181,300
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 0
|
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
slapenrich
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00004223
|
Completed
| 2
|
1999-12-01
| null | null | null | null |
Phase II+
| 1,683,627,181,300
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
cancer_biomarkers
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00004223
|
Completed
| 2
|
1999-12-01
| null | null | null | null |
Phase II+
| 1,683,627,181,300
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00004223
|
Completed
| 2
|
1999-12-01
| null | null | null | null |
Phase II+
| 1,683,627,181,300
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00004223
|
Completed
| 2
|
1999-12-01
| null | null | null | null |
Phase II+
| 1,683,627,181,300
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
slapenrich
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00004223
|
Completed
| 2
|
1999-12-01
| null | null | null | null |
Phase II+
| 1,683,627,181,300
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
cancer_biomarkers
|
affected_pathway
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00004223
|
Completed
| 2
|
1999-12-01
| null | null | null | null |
Phase II+
| 1,683,627,181,300
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00004223
|
Completed
| 2
|
1999-12-01
| null | null | null | null |
Phase II+
| 1,683,627,181,300
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
europepmc
|
literature
| 413,311
|
ENSG00000258947
|
MONDO_0001187
|
NCT00004223
|
Completed
| 2
|
1999-12-01
| null | null | null | null |
Phase II+
| 1,683,627,181,300
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF intolerant
|
Detected in many
|
Tissue enriched
|
from1to10
|
slapenrich
|
affected_pathway
| 413,311
|
ENSG00000261456
|
Orphanet_59305
|
NCT02639650
|
Unknown status
| 3
|
2016-03-01
| null | null | null |
Phase III+
|
Phase II+
| 670,014,899,450
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null | null |
Detected in single
|
Tissue enhanced
|
none
|
chembl
|
known_drug
| 413,311
|
ENSG00000268089
|
MONDO_0024355
|
NCT00611195
|
Completed
| 4
|
2008-01-01
| null | null |
Phase IV
|
Phase III+
|
Phase II+
| 704,374,636,712
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0005741
|
infectious disease
|
Other
| null | null |
Detected in some
|
Tissue enriched
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000269858
|
EFO_0008585
|
NCT04803864
|
Recruiting
| 2
|
2021-06-10
| null | null | null | null |
Phase II+
| 661,424,963,945
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000319
|
cardiovascular disease
|
Other
| 1
| null |
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000269858
|
EFO_0008585
|
NCT04803864
|
Recruiting
| 2
|
2021-06-10
| null | null | null | null |
Phase II+
| 661,424,963,945
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000319
|
cardiovascular disease
|
Other
| null | null |
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000269858
|
EFO_0008585
|
NCT04803864
|
Recruiting
| 2
|
2021-06-10
| null | null | null | null |
Phase II+
| 661,424,963,945
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000319
|
cardiovascular disease
|
Other
| null | null |
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000274286
|
EFO_0009085
|
NCT01785693
|
Completed
| 4
|
2013-01-30
| null | null |
Phase IV
|
Phase III+
|
Phase II+
| 1,374,389,535,088
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000319
|
cardiovascular disease
|
Other
| null | null |
Detected in many
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000278195
|
MONDO_0008315
|
NCT01646684
|
Completed
| 1
|
2013-03-08
| null | null | null | null | null | 1,168,231,105,229
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null | null |
Detected in some
|
Tissue enhanced
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000278195
|
MONDO_0008315
|
NCT01646684
|
Completed
| 1
|
2013-03-08
| null | null | null | null | null | 1,168,231,105,229
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null | null |
Detected in some
|
Tissue enhanced
|
from1to10
|
slapenrich
|
affected_pathway
| 413,311
|
ENSG00000278195
|
MONDO_0008315
|
NCT01313559
|
Terminated
| 2
|
2011-06-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 154,618,824,322
|
Slow accrual
|
Phase 2
|
30/06/2011
|
Terminated
|
25/04/2018
|
29/11/2012
|
Insufficient_Enrollment
|
Neutral
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null | null |
Detected in some
|
Tissue enhanced
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000278195
|
MONDO_0008315
|
NCT01313559
|
Terminated
| 2
|
2011-06-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 154,618,824,322
|
Slow accrual
|
Phase 2
|
30/06/2011
|
Terminated
|
25/04/2018
|
29/11/2012
|
Insufficient_Enrollment
|
Neutral
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null | null |
Detected in some
|
Tissue enhanced
|
from1to10
|
slapenrich
|
affected_pathway
| 413,311
|
ENSG00000278195
|
MONDO_0008315
|
NCT00510224
|
Terminated
| 2
|
2007-07-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 300,647,711,166
|
Stopped at interim analyses phase due to lack of efficacy
|
Phase 2
|
31/07/2007
|
Terminated
|
11/12/2013
|
31/08/2009
|
Negative
|
Negative
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null | null |
Detected in some
|
Tissue enhanced
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000278195
|
MONDO_0008315
|
NCT00510224
|
Terminated
| 2
|
2007-07-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 300,647,711,166
|
Stopped at interim analyses phase due to lack of efficacy
|
Phase 2
|
31/07/2007
|
Terminated
|
11/12/2013
|
31/08/2009
|
Negative
|
Negative
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null | null |
Detected in some
|
Tissue enhanced
|
from1to10
|
slapenrich
|
affected_pathway
| 413,311
|
ENSG00000278195
|
MONDO_0008315
|
NCT00166725
|
Completed
| 2
|
2004-02-01
| null | null | null | null |
Phase II+
| 867,583,394,385
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null | null |
Detected in some
|
Tissue enhanced
|
from1to10
|
chembl
|
known_drug
| 413,311
|
ENSG00000278195
|
MONDO_0008315
|
NCT00166725
|
Completed
| 2
|
2004-02-01
| null | null | null | null |
Phase II+
| 867,583,394,385
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null | null |
Detected in some
|
Tissue enhanced
|
from1to10
|
slapenrich
|
affected_pathway
| 413,311
|
ENSG00000278195
|
MONDO_0015277
|
NCT01625520
|
Completed
| 2
|
2012-02-01
| null | null | null | null |
Phase II+
| 755,914,244,980
| null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null | null |
Detected in some
|
Tissue enhanced
|
from1to10
|
chembl
|
known_drug
| 413,311
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.